| Bioactivity | TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth[1]. | ||||||||||||
| Invitro | TL02-59 (0.1-1000 nM; 6 hours) potently inhibits Fgr autophosphorylation in TF-1 cells, with paritial inhibition at 0.1-1 nM and complete inhibition above 10 nM. Hck, Lyn and Flt3 are inhibited in the 100 to 1000 nM range[1]. TL02-59 inhibits the growth and induced apoptosis of AML cell lines expressing this kinase with single-digit nM potency[1]. TL02-59 induces growth arrest in primary AML bone marrow samples[1]. Western Blot Analysis[1] Cell Line: | ||||||||||||
| Name | TL02-59 | ||||||||||||
| CAS | 1315330-17-6 | ||||||||||||
| Formula | C32H34F3N5O4 | ||||||||||||
| Molar Mass | 609.64 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
TL02-59
CAS: 1315330-17-6 F: C32H34F3N5O4 W: 609.64
TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 inhibits Lyn and
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.